Baby Formula NEC Lawsuit
Updated October 1, 2026. MDL-3026, before Judge Rebecca Pallmeyer in the Northern District of Illinois, consolidates lawsuits alleging that Abbott and Mead Johnson cow's-milk-based preterm formulas increase the risk of necrotizing enterocolitis (NEC) in premature infants. The picture is mixed: state juries have returned large verdicts, but three federal bellwethers were dismissed on summary judgment, the Seventh Circuit affirmed one on July 24, 2026, and a published Illinois opinion reversed the $60 million Watson verdict. In late August the picture moved again: on August 31, 2026, a federal jury returned a defense verdict for Mead Johnson in Inman, the first federal NEC bellwether to reach a jury. Earlier, a settlement filing on August 17 ended Abbott's appeal of the $495 million Gill verdict, and on August 20 Abbott agreed to resolve Gill and claims for about 2,000 additional infants for an aggregate of about $670 million. Gill's share was not disclosed. There is still no global settlement.
Key Takeaways
- NEC is the most common serious GI disease in newborns—it can be fatal or cause lifelong complications
- Cochrane review (2024) found human milk reduces NEC risk by ~50% compared to formula (high certainty evidence)
- About 7% of very low birth weight infants develop NEC—prematurity is the primary risk factor
- On Aug 20, Abbott agreed to resolve the $495M Gill verdict and claims for about 2,000 more infants for an aggregate of about $670M (Gill's share not disclosed); there is still no global settlement
- Federal bellwethers against Abbott were dismissed on summary judgment, but the first to reach a jury, Inman v. Mead Johnson, ended in a defense verdict on August 31, 2026
- Lawsuits allege manufacturers knew the risk but failed to warn parents and healthcare providers
Key Facts (October 2026)
| Pending Lawsuits | 844 cases in federal MDL |
| Condition Alleged | Necrotizing Enterocolitis (NEC) |
| Defendants | Abbott Laboratories, Mead Johnson (Reckitt) |
| Products at Issue | Similac, Enfamil preterm formulas & fortifiers |
| Population Affected | Premature/low birth weight infants |
| Bellwether Status | First federal bellwether to reach a jury, Inman v. Mead Johnson, ended in a defense verdict (August 31, 2026); earlier Abbott bellwethers were dismissed on summary judgment |
| Global Settlement | None global. On Aug 20, Abbott agreed to resolve the Gill case and claims for about 2,000 more infants for about $670M in aggregate (Gill's share not disclosed) |
| Presiding Judge | Hon. Rebecca R. Pallmeyer |
| Court | N.D. Illinois (Chicago) |
| Can You Still File? | Yes, lawsuits are being filed |
Case Growth in 2025
Families continue to file lawsuits after learning about the link between cow's milk formula and NEC in premature infants. Case count has grown 34% since January 2025.
Source: JPML MDL Statistics Reports, January 2025-October 2026
1 What Is This Lawsuit?
The Abbott/Mead Johnson NEC MDL consolidates lawsuits from families of premature infants who developed necrotizing enterocolitis (NEC) after being fed cow's milk-based infant formulas, including Similac and Enfamil products.
The Core Allegation
Plaintiffs allege Abbott and Mead Johnson knew that cow's milk-based formulas significantly increase NEC risk in preterm infants compared to human milk, but failed to adequately warn parents and healthcare providers about this risk.
The Science
A 2024 Cochrane systematic review—the highest level of medical evidence—found that donor human milk reduces NEC risk by approximately 50% compared to formula (high certainty evidence based on 12 trials).
This is an emotionally devastating litigation involving the most vulnerable patients—premature babies in NICUs. Claims include failure to warn, negligence, and product liability. Families seek compensation for medical expenses, wrongful death, and the profound suffering caused by NEC.
2 What Is Necrotizing Enterocolitis (NEC)?
Medical Emergency
NEC is the most common, serious gastrointestinal disease affecting newborn infants. Healthcare providers consider NEC a medical and surgical emergency that requires immediate intervention.
In NEC, the intestinal tissue becomes inflamed and begins to die (necrosis). In severe cases, the intestinal wall can perforate (develop holes), allowing bacteria to leak into the abdomen and bloodstream, causing life-threatening infection.
Who Is at Risk?
The primary risk factor is prematurity and low birth weight. According to NICHD:
- All infants born preterm (<37 weeks) or with low birth weight (<5.5 lbs) are at increased risk
- The smaller the infant or the more premature, the greater the risk
- About 7% of very low birth weight infants develop NEC
- About 9% of cases occur in full-term infants (often with other conditions)
NEC Staging (Bell System)
Stage 1: Suspected NEC
Bloody stools, lethargy, slow heart rate, unstable temperature, mild abdominal bloating, vomiting
Stage 2: Definite NEC
Stage 1 symptoms plus reduced platelets, no bowel sounds, abdominal pain, gas in intestinal walls
Stage 3: Advanced NEC
Stages 1-2 plus apnea, low blood pressure, inflammation, possible intestinal perforation
3 Consequences of NEC
Mortality
- NEC is a leading cause of infant mortality
- Mortality can exceed 20-30% in severe cases requiring surgery
- Many cases involve wrongful death claims
Long-Term Complications
- Short bowel syndrome—requires long-term IV nutrition
- Multiple surgeries including bowel resections
- Neurodevelopmental delays and growth problems
4 The Scientific Evidence
Cochrane Review (2024) — Highest Level Evidence
| Key Finding | Human milk reduces NEC risk by ~50% vs formula |
| Risk Ratio | 0.53 (95% CI: 0.37-0.76) |
| Evidence Quality | High certainty (GRADE assessment) |
| Data Source | 12 randomized trials, 2,296 infants |
PMID: 39239939 — Published September 2024
Why Human Milk Protects
Important Context
Formula remains medically necessary when human milk isn't available. Not all formula-fed preterm infants develop NEC, and NEC has multiple contributing factors. The issue in this litigation is whether manufacturers adequately warned about the increased risk.
5 Products at Issue
A Abbott Products
- Similac Special Care (preterm hospital use)
- Similac NeoSure (post-discharge)
- Abbott human milk fortifiers
M Mead Johnson Products
- Enfamil Premature (hospital use)
- Enfacare (post-discharge)
- Mead Johnson human milk fortifiers
6 Verdict and Appeal Tracker
This is the most complicated part of the NEC litigation, and it is where the honest picture matters most. The MDL was consolidated in the Northern District of Illinois before Judge Rebecca Pallmeyer in 2022, but the largest jury awards have come in state court, and the appellate record cuts against plaintiffs on causation. Gross plaintiff verdicts total about $625 million. The $60 million Watson verdict was reversed. A settlement filing on August 17, 2026 ended Abbott's appeal of the $495 million Gill verdict to the Missouri Supreme Court, and on August 20 Abbott agreed to resolve Gill and NEC claims for about 2,000 additional infants for an aggregate of about $670 million, according to its SEC filing. Gill's share was not disclosed. The post-trial status of the $70 million Cook County verdict is not verified. Mead Johnson won the first federal bellwether to reach a jury, Inman, on August 31, 2026. No global settlement has been announced. The table is updated on every verdict and appellate move.
| Case | Venue | Verdict | Status |
|---|---|---|---|
| Gill v. Abbott | St. Louis, MO (state) | $495M plaintiff ($95M compensatory + $400M punitive) | Affirmed May 5, 2026 (unpublished); transfer denied June 22, 2026. A settlement filing on August 17, 2026 ended Abbott's appeal to the Missouri Supreme Court. Resolved in Abbott's August 20, 2026 agreements (about $670 million in aggregate, see next row); Gill's share was not disclosed. |
| Abbott settlement (Gill + approx. 2,000 more infants) | MDL-3026 + state (three firms) | About $670M in aggregate (includes Gill), August 20, 2026 | Abbott agreed to resolve the Gill case above plus NEC claims for about 2,000 additional infants, for an aggregate of about $670 million (per its August 20, 2026 SEC filing; Gill's share not disclosed). The additional claims are held by TorHoerman Law, the Holland Law Firm, and Stranch, Jennings & Garvey, across federal and state court. A partial settlement, not a global MDL resolution; Abbott admitted no liability. |
| Cook County consolidated (4 plaintiffs) | Cook County, IL (state) | $70M plaintiff ($53M compensatory + $17M punitive) | April 9-10, 2026. Post-trial status not verified. |
| Watson v. Mead Johnson | St. Clair County, IL (state) | $60M plaintiff | Reversed June 12, 2026 in a published opinion applying the learned intermediary doctrine; new trial. |
| Whitfield | St. Louis, MO (state) | Defense | Vacated March 13, 2025 and a new trial ordered; the Missouri Court of Appeals (Eastern District) affirmed the new-trial order August 11, 2026. Retrial date not set. |
| K.H. | St. Louis, MO (state) | Defense | July 2, 2026; stands. Jury found against the plaintiff on specific causation. |
| Mar v. Abbott | MDL-3026 (federal) | Defense summary judgment | Affirmed by the Seventh Circuit July 24, 2026 on warning causation. |
| Diggs v. Abbott | MDL-3026 (federal) | Defense summary judgment | July 2025. |
| Third federal bellwether | MDL-3026 (federal) | Defense summary judgment | October 2025. |
| Inman v. Mead Johnson | MDL-3026 (federal, N.D. Ill.) | Defense verdict (unanimous), August 31, 2026 | First federal NEC bellwether to reach a jury. The jury found that the death resulted from extreme prematurity, not Enfamil, and rejected the claim that Mead Johnson should have reformulated since 2015. The verdict stands, subject to any post-trial motions. |
These are jury verdicts and court rulings. The underlying claim, that cow's-milk-based preterm formula increases the alleged risk of NEC, remains contested, and the first three federal bellwethers ended in defense summary judgments, one of them affirmed by the Seventh Circuit. Dollar figures are jury verdicts, except Abbott's roughly $670 million aggregate settlement, and none is a per-case value or projection. There is no global settlement in this litigation; Abbott's August 2026 agreements resolve Gill and claims for about 2,000 additional infants.
Read the pattern rather than any single number. In federal court, the early bellwethers were dismissed on summary judgment in the defense's favor. On July 24, 2026 the Seventh Circuit affirmed one of those defense dismissals in Mar v. Abbott. The first federal NEC bellwether to reach a jury was Inman v. Mead Johnson, which had survived summary judgment in May 2026 and went to trial in August; on August 31, 2026 the jury returned a defense verdict for Mead Johnson, finding the death was caused by extreme prematurity rather than Enfamil.
7 The Legal Landscape: Learned Intermediary, Forum, and the Federal Consensus
Three developments explain why this tort is harder for plaintiffs than the raw verdict numbers suggest, and a page that states them honestly is more useful than one that hides them.
The learned intermediary split
The learned intermediary doctrine holds that a manufacturer's duty to warn runs to the prescribing physician, not directly to the patient, so a failure-to-warn claim can fail if the doctor was adequately informed. Two courts split on whether it applies to preterm formula within about seven weeks of each other. A Missouri court rejected the defense for preterm formula, but that ruling is unpublished and non-precedential. Then, on June 12, 2026, Illinois's Fifth District adopted the doctrine for preterm formula in a published opinion and used it to reverse the $60 million Watson verdict and order a new trial. A published appellate opinion carries far more weight than an unpublished trial-court ruling, so the practical effect is that the doctrine now raises the proof burden across Illinois, one of the most active venues in the litigation.
The Deppa forum ruling
On December 12, 2025, an Illinois appellate court dismissed 23 of 29 Cook County cases on forum non conveniens grounds, leaving only the six Illinois-resident cases. Cook County had been a favorable venue for out-of-state plaintiffs, and the ruling materially narrows where these cases can be brought.
The federal agencies' consensus
On October 2, 2024, the FDA, CDC, and NIH issued a joint statement, and it is the central defense exhibit. Stated fairly, it found no conclusive evidence that preterm infant formula causes NEC, strong evidence that human milk is protective, and evidence that supports the absence of human milk rather than formula exposure itself as the associated risk, with preterm birth as the primary risk factor. It also described specialty formulas as critically important and part of the standard of care when human milk is unavailable or insufficient. The plaintiffs' case is not that formula is unsafe for all babies; it is that parents of preterm infants were not adequately informed of the relative risks. That is the alleged failure the litigation turns on.
What the live defenses are, and are not
There is no federal preemption ruling in this litigation at any level, so preemption is not the battleground here that it is in some device cases. The live defenses are warning causation (whether a different warning would have changed the outcome), specific causation (whether the formula caused this infant's NEC rather than prematurity itself), and the learned intermediary doctrine. Abbott won the first three federal bellwethers on summary judgment, and the Seventh Circuit affirmed one of those, on warning causation, in July 2026. In the first federal bellwether to reach a jury, Mead Johnson won a defense verdict in Inman on August 31, 2026.
8 Who May Qualify
Families may be eligible to file a lawsuit if their child meets these criteria:
Born Prematurely
Infant was born before 37 weeks gestation, especially very low birth weight (<1,500 grams)
Fed Cow's Milk Formula
Was fed Similac, Enfamil, or similar cow's milk-based preterm formula or fortifier in the NICU
Diagnosed with NEC
Infant was diagnosed with necrotizing enterocolitis during NICU stay
Have Medical Documentation
Medical records document the formula feeding and NEC diagnosis
9 Frequently Asked Questions
Is this about the 2022 Abbott formula recall?
Does this mean formula is dangerous for all babies?
Why do hospitals still use formula if human milk is safer?
What is the learned intermediary doctrine and why does it matter here?
What did the Seventh Circuit decide in July 2026?
Is there a NEC settlement?
What compensation might be available?
Is it too late to file a lawsuit?
Who are the defendants?
Free, confidential review. No obligation.
Sources & References
9 sources citedJudicial Panel on Multidistrict Litigation (JPML) — Official MDL statistics
NICHD Necrotizing Enterocolitis — NIH disease information
Cochrane Review (2024) — Donor human milk vs formula for NEC prevention (PMID: 39239939)
CDC NCHS Birth Statistics — US preterm birth data
WHO Preterm Birth Fact Sheet — Global prematurity data
AAP Policy Statement (2017) — Donor human milk for high-risk infants
Reuters (August 19, 2026), Abbott settles appeal over $495 million infant formula verdict
Abbott Laboratories, Form 8-K, Item 8.01 (filed August 20, 2026), resolution of the Gill case and NEC claims for about 2,000 additional infants
Court records and JPML case statistics. Data current as of October 2026.
Did your premature baby develop NEC after formula feeding?
If your premature infant was fed a cow's-milk-based formula or fortifier in the NICU and was diagnosed with necrotizing enterocolitis, your family may be able to file a claim. Deadlines for a child's claim vary by state and are often tolled during minority, but they do run, so it is worth checking.
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content.
Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.